Jubbonti (denosumab-bbdz) — HCPCS Q5136

Jubbonti is FDA-interchangeable with Prolia FDA Purple Book verified Sep 2026

Jubbonti cleared the FDA's higher interchangeable bar on the same day it was licensed as biosimilar — the first denosumab biosimilar to do so.

The FDA Purple Book gives Jubbonti one date for both approval and interchangeability: March 5, 2024. No other denosumab biosimilar was designated interchangeable before it. Being first came with a 12-month first-interchangeable exclusivity for Jubbonti and Wyost, which kept other denosumab biosimilars from launching as interchangeable. When it expired on October 29, 2025, most later products picked up that date in the Purple Book's interchangeable column. It marks the end of Jubbonti's exclusivity, not a day on which the FDA ruled on each of them. See the hub page for the full timeline across all nine pairs.

Jubbonti vs. Wyost — one code, two doses CMS HCPCS + FDA verified Sep 2026

Sandoz markets denosumab-bbdz under two brand names for two dosing lines, and both bill the same HCPCS code, Q5136.

Both are denosumab-bbdz, both are Sandoz products, and both bill Q5136. Because the code does not distinguish them, the billed unit count is what separates a Jubbonti claim from a Wyost claim on the claim form: 60 units for Jubbonti, 120 for Wyost. Confirm which product was actually administered against the NDC drawn before submitting the claim — billing 60 units when the patient received Wyost, or 120 when they received Jubbonti, is the same class of error that occurs between reference Prolia and Xgeva on their shared code, J0897.

Dosing FDA label verified Sep 2026

One fixed dose, one fixed schedule — identical to reference Prolia. No induction phase and no weight-based adjustment.

Because the 60 mg fixed dose exactly matches the 60 mg fixed syringe fill, there is normally nothing left over to waste on a Jubbonti claim — see modifiers for the JZ/JW consequence of that.

NDC reference FDA NDC Directory, Sep 2026

For CMS-1500 Box 24A, pad the product segment to four digits: 61314-240-63 becomes 61314-0240-63. Check the syringe before billing.

Administration codes CPT verified Sep 2026

Jubbonti is a subcutaneous injection, not an infusion. Administration bills 96372 alone.

Modifiers — JZ, JW, and TB (340B) CMS verified Sep 2026

JZ is the norm on essentially every Jubbonti claim because the fixed 60 mg dose exactly matches the fixed syringe size. JW is rare. TB is the sole 340B modifier.

JZ — required when no drug is discarded

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Because Jubbonti's one fixed dose (60 mg) exactly matches its one fixed syringe size (60 mg), there is normally nothing left over to waste — append JZ to the Q5136 line on essentially every claim.

JW — required for documented waste

JW applies only on the rare occasion a syringe is opened and the full 60 mg dose is not administered. Document the discarded amount in the chart and bill it on a separate line, same date of service, same HCPCS code.

TB — the only current 340B modifier

A hospital that bought Jubbonti through 340B and bills Medicare reports TB on the Q5136 line. JG has not been used since CMS discontinued it on January 1, 2025.

Modifier 25 — same-day E/M

Append modifier 25 to the same-day E/M code only if a significant, separately identifiable evaluation occurred beyond the routine pre-injection check-in, which is bundled into the administration code.

ICD-10-CM codes for Jubbonti and Wyost claims Codes as on our Prolia and Xgeva pages

The diagnosis in Box 21 should match the product drawn: a bone-loss code for a 60-unit Jubbonti line, a cancer code for a 120-unit Wyost line.

Jubbonti, 60 mg (osteoporosis and treatment-related bone loss)

Wyost, 120 mg (oncology)

Hypocalcemia, E83.51, is a reason to hold a dose, not a reason to give one, so never put it on a Q5136 line as the diagnosis. Jubbonti's full indication notes live on the Prolia page, and Wyost's on the Xgeva page.

Claim form field mapping CMS-1500 field reference

CMS-1500 / 837P (physician office; POS 11) example for a standard 60 mg Jubbonti dose.

Payer policy snapshot — who prefers Jubbonti Reviewed Sep 2026, 27-payer corpus

Jubbonti itself is preferred or step-first in 9 of the 27 commercial payer policies surveyed. Two more prefer only its 120 mg twin, Wyost.

Preferred for Jubbonti (60 mg line): BCBS Louisiana, BCBS Massachusetts, BCBS Minnesota, BCBS Nebraska, BCBS South Carolina, Blue Shield of California, Florida Blue, Independence Blue Cross, and Wellmark BCBS. Preferred for Wyost only (120 mg line): Centene/Ambetter and Regence BCBS. Their preferred lists name Wyost and do not name Jubbonti.

Several of the nine make other products wait behind Jubbonti. BCBS Louisiana, for example, approves Prolia, Stoboclo or Conexxence only after the patient has tried and failed Jubbonti, Bildyos and Enoby. Going the other way, Jubbonti is non-preferred at Anthem (which prefers Prolia), Excellus (which prefers Bildyos and Enoby) and UnitedHealthcare.

Jubbonti is not on BCBS Mississippi's covered list. Per the payer's policy, the covered denosumab products are Stoboclo/Osenvelt, Bildyos/Bilprevda and Enoby/Xtrenbo, and biosimilars it does not name are non-formulary. Our copy of that policy is filed under a web address for a different policy, so call BCBS Mississippi before scheduling a Jubbonti patient there.

See the full payer-by-payer comparison across all nine biosimilar pairs on the denosumab biosimilars hub.

Medicare reimbursement CMS Q4 2026 (live)

Quarterly ASP from the CMS Part B Drug Pricing File.

With the 96372 administration allowance ($15.36, 2026 Medicare PFS national non-facility rate) added, a 60 mg Jubbonti claim totals $1,634.82 before sequestration, against $1,806.72 for the equivalent Prolia claim.

Coverage

CMS MCD Article A52399 ("Billing and Coding: Denosumab and biosimilars") lists Q5136 for Jubbonti or Wyost. For the MAC-level ICD-10 ranges, see Medicare covered diagnoses for denosumab.

Canonical code source: CMS HCPCS quarterly update file.

Patient assistance — Sandoz programs Status checked Sep 12, 2026

Sandoz One Source Co-Pay Program is open: eligible commercially insured patients may pay as little as $0 for Jubbonti. Medicare, Medicaid and other government coverage are excluded, and it covers the drug only, not the administration. Verify current terms at sandoz-onesource.com/jubbonti before quoting a figure to a patient.

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Jubbonti?

Jubbonti (denosumab-bbdz) is billed under HCPCS Q5136, billed 1 unit = 1 mg, the same unit basis as reference Prolia (J0897). The standard 60 mg osteoporosis dose is 60 units.

Is Jubbonti interchangeable with Prolia?

Yes. The FDA Purple Book lists Jubbonti as interchangeable with Prolia from March 5, 2024, the day it was approved, which made it the first interchangeable denosumab biosimilar. Each plan's preferred-product rules still decide which denosumab product gets paid.

What is Wyost, and does it bill the same code as Jubbonti?

Wyost is the 120 mg Xgeva-line twin of Jubbonti — same manufacturer (Sandoz), same active ingredient (denosumab-bbdz), same HCPCS code, Q5136. Jubbonti is dosed 60 mg subcutaneously every 6 months for osteoporosis; Wyost is dosed 120 mg every 4 weeks for oncology indications. The units on the claim, 60 versus 120, are what separate them, since both bill Q5136.

Which payers prefer Jubbonti (Q5136)?

Nine of the 27 commercial payer policies in our corpus prefer Jubbonti: BCBS Louisiana, BCBS Massachusetts, BCBS Minnesota, BCBS Nebraska, BCBS South Carolina, Blue Shield of California, Florida Blue, Independence Blue Cross and Wellmark BCBS. Centene/Ambetter and Regence BCBS prefer only Wyost, the 120 mg product on the same code. UnitedHealthcare prefers Prolia and Stoboclo and wants a trial of both before approving Jubbonti.

What is the Q4 2026 Medicare reimbursement for Q5136?

Q4 2026 ASP+6% for Q5136 Jubbonti is $26.991 per 1 mg unit — about 9.6% below reference Prolia's $29.856 in the same quarter. A 60 mg dose is 60 units, pricing to $1,619.46 before the administration allowance and sequestration.

Is manufacturer assistance available for Jubbonti?

For commercially insured patients, yes: the Sandoz One Source Co-Pay Program is open, with costs as low as $0 (Medicare, Medicaid and other government plans excluded). The Sandoz Patient Assistance Program, the free-drug route, is closed for Jubbonti in our record, because its application instructions name only Zarxio and Tyruko. Confirm with Sandoz before referring a patient.

Source documents

1. FDA Purple Book Database — full monthly data file, August 2026 release
   BLA761362; approval and interchangeable-designation date; reference product
2. DailyMed — JUBBONTI (denosumab-bbdz) prescribing information
   Presentation; labeled dose and interval
3. openFDA NDC Directory — denosumab listings
   NDC 61314-240-63 and its marketing start date
4. CMS MCD Article A52399 — Billing and Coding: Denosumab and biosimilars
   HCPCS Q5136 descriptor and code verification
5. CMS — Medicare Part B Drug ASP Pricing File
   Q4 2026 quarterly file (Q5136, J0897)
6. CMS — Medicare Part B inflation rebate guidance: use of the 340B modifier
   JG modifier discontinued for all 340B-covered entities effective January 1, 2025; TB is the sole 340B modifier
7. Sandoz One Source — Jubbonti co-pay program
   Co-pay assistance program terms and enrollment
8. CareCost Estimate — Prolia reference (J0897 and the full denosumab biosimilar family)
   ICD-10 by indication, boxed warnings, pre-treatment workup, MUE
9. CareCost Estimate — Denosumab biosimilars hub
   Full nine-pair comparison, payer-by-payer preference split, price spread

About this page

Medicare ASP pricing for Q5136 is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding, payer-policy, and assistance-program content is reviewed at least quarterly and updated whenever the manufacturer program, FDA label, or a major payer policy changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• Sep 21, 2026 — Initial publication. Jubbonti-specific (Q5136) billing reference: interchangeable-status framing, NDC 61314-240-63 from the FDA NDC Directory, single subcutaneous admin code (96372), JZ/JW/TB modifier guidance, the Wyost 120 mg twin on the same code, 2026 payer preference snapshot (9 of 27 payers for Jubbonti, 2 more for Wyost only), and Sandoz One Source assistance status.

Methodology

Every claim on this page is sourced inline. The NDC comes from the FDA NDC Directory and dosing from the DailyMed label; the ASP figure is read live from the CMS Part B ASP file; payer rules are read from each plan's published medical policy; assistance-program status is read from the manufacturer's own program page. We do not paraphrase from billing-software vendor blogs, and we flag anything not yet SME-verified rather than assert it.